Surrozen, Inc./DE (SRZN) Spending and interest coverage
- R&D / revenue · 12 months: Value 300.38%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 60.85%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 300.38% | Research and development expense / revenue. Period ending 2026-06-30. $34.58M ÷ $11.51M × 100 ≈ 300.38% |
| Stock-based compensation / revenue · 12 months | 60.85% | Share-based compensation / revenue. Period ending 2026-06-30. $7.00M ÷ $11.51M × 100 ≈ 60.85% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 34.58M USD | Research and Development Expense |
| Revenue | 11.51M USD | |
| Stock-based compensation | 7.00M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -44.35M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $34.58M | $11.51M | $7.00M | $-44.35M | (m) | 300.38% | 60.85% | (m) | (m) |
| 2026-03-31 | $32.13M | $7.49M | $5.11M | $-43.00M | (m) | 428.81% | 68.13% | (m) | (m) |
| 2025-12-31 | $29.36M | $3.48M | $3.83M | $-42.09M | (m) | 844.55% | 110.30% | (m) | (m) |
| 2025-09-30 | $25.72M | $3.60M | $3.73M | $-38.05M | (m) | 713.76% | 103.58% | (m) | (m) |
| 2025-06-30 | $23.15M | (m) | $3.77M | $-25.93M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $22.44M | (m) | $3.92M | $-25.96M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $21.13M | $10.65M | $4.11M | $-25.54M | (m) | 198.33% | 38.61% | (m) | (m) |
| 2024-09-30 | $21.88M | (m) | $4.39M | $-26.67M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $22.79M | (m) | $4.26M | $-39.09M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $24.39M | (m) | $4.27M | $-40.32M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $27.23M | (m) | $4.37M | $-45.78M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $30.57M | (m) | $4.75M | $-38.23M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $33.08M | (m) | $4.91M | $-40.64M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $35.73M | (m) | $4.73M | $-44.44M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $37.01M | (m) | $4.52M | $-44.34M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $38.47M | (m) | $3.67M | $-57.16M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $40.26M | (m) | $3.20M | $-57.27M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $40.95M | (m) | $2.76M | $-55.85M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $40.18M | (m) | $2.32M | $-54.39M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |